iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing

News
- Oct 11
iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital
- Jul 5
iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy
- Dec 14, 2022
iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023
- Sep 18, 2022
iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track
- Aug 30, 2022
iQure Pharma Secures $600K in Commitments in Early Closing to Research Neuropathic Pain Therapies
- Apr 7, 2022
iQure Pharma Targets Future with New Board Appointments
- Mar 1, 2022
iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum
- Feb 16, 2021
Company signed Agreement with University of Arizona for non-opioid treatment of post-operative pain
- Sep 14, 2020
iQure Pharma Inc. Secures Private Investment of $100,000
- May 25, 2020
iQure Pharma Inc. Secures Additional Investment of $50,000
- Dec 16, 2019
Chairman Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January